GBS Inc Reports First Quarter 2021 Financial Results and Recent Business Highlights streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
IQX Limited (NSX:IQX) Progress of Clinical Programs
Progress of Clinical ProgramsSydney, April 29, 2021 AEST (ABN Newswire) - iQX Limited (iQX Ltd) (
NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) in which iQX Ltd holds a 19% equity position, has received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a clinical validation study to test patient samples from a COVID-19 repository. The study follows a partnership with the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute), through Life Science Biosensor Diagnostics Pty Ltd subsidiary, GBS Inc. (
Nasdaq:GBS), a Delaware corporation, to develop a novel diagnostic SARS-CoV-2 test.
GBS Inc Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
GBS opened for trading and both ended up breaking in their debuts.
Shares of Inhibikase (ticker: IKT) rose as much as 18% Wednesday. The stock opened at $10.67, hit a high of $11.80, and closed at $9.90. Because it finished 10 cents below its $10 IPO price, Inhibikase is considered a broken deal.
Late Tuesday, Inhibikase raised $18 million after cutting the size of its deal but pricing significantly above its expected range. The Atlanta company had initially planned to sell 2,272,727 shares at $10 to $12, then cut it to 1.4 million, which was then reduced to the current 1.8 million shares at $10 each.
Inhibikase was scheduled to trade last month, but delayed the deal. ThinkEquity, a division of Fordham Financial Management, is the underwriter on the deal.